SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Clinical research
The 5 Most Painful Clinical Trial Failures of 2025
Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting neurological diseases. Some failures split up partners, and one particularly egregious case even led to the demise of an entire company.
December 15, 2025
 · 
9 min read
 · 
Tristan Manalac
vintage rocket takes flight with uncertain trajectory, concrete background. false start concept. 3d render.
Clinical research
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT modality, including from GSK, Merck and Roche.
December 12, 2025
 · 
3 min read
 · 
Annalee Armstrong
Pictured: Illustration of antibodies attacking a nerve cell
Approvals
Amgen Scores Uplizna Expansion Into Generalized Myasthenia Gravis
Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for IgG4-related disease in April.
December 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands in black and white dropping a collection of pills on a pink background
Approvals
GSK’s Blujepa Opens First New Class of Gonorrhea Antibiotic in More Than 30 Years
Blujepa is also approved for uncomplicated urinary tract infection in females 12 years and older.
December 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Close-Up Of Syringe With Bottles Against Blue Background
Vaccines
CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths
The 2024–2025 formulations of COVID-19 vaccines had an effectiveness rate of 76% at preventing emergency or urgent care visits in children aged 9 months through four years, according to a new report.
December 12, 2025
 · 
2 min read
 · 
Tristan Manalac
complex messy management, bureaucracy,red tape,organization and innovation,business disruption, complicated business process
Regulatory
Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot
With five CDER leaders in one year and regulatory proposals coming “by fiat,” the FDA is only making it more difficult to bring therapies to patients.
December 12, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Hand holds a cut-out puzzle piece shaped like a human brain, backlit by sunlight against a bright yellow background, symbolizing creativity and problem-solving.
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
 · 
1 min read
 · 
Annalee Armstrong
Dartboard with three darts in the bullseyes. 3D illustration
Obesity
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.
December 11, 2025
 · 
3 min read
 · 
Annalee Armstrong
Concept of freedom, with a man who opens a breach in a wall to escape from his prison and pass from the shadows to the light.
FDA
Opinion: FDA Is Built on Predictability and Expertise, Not Norm-Breaking
The FDA is becoming deeply compromised and increasingly at risk of being permanently transformed in ways contrary to its mission, history and culture.
December 11, 2025
 · 
5 min read
 · 
Steven Grossman
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS